The article compares Amgen (AMGN) and Johnson & Johnson (JNJ) as two different healthcare investment paths. Amgen reported 2025 revenue of about $36.7 billion, up roughly 10%, and net income of about $7.7 billion, with McKesson, Cencora and Cardinal Health together accounting for 77% of gross revenues. Johnson & Johnson posted revenue of about $94.2 billion, up 6%, net income of about $26.8 billion, free cash flow of about $19.7 billion and a debt-to-equity ratio of about 0.6x, while Amgen's was nearly 6.3x. Risks cited include drug price pressure for both companies, Amgen's production concentrated in Puerto Rico and California and an IRS tax dispute, and J&J's talc-related product liability claims and patent challenges. The article says Amgen appears more affordable based on future earnings, while J&J carries significantly less debt relative to its equity.
Summary written by Upside AI from the original article. Read the source for full details.
Original headline: Amgen vs . Johnson & Johnson : Which Healthcare Giant Has the Better Stock to Buy ?
Read the original on fool.com ↗
Keywords
Open a keyword to see other news on the same topic.
Related news
- Should You Invest in This Dividend King on the Dip?
Johnson & Johnson (JNJ) shares fell significantly after its third-quarter results, even though the company beat expectations and slightly raised its full-year guidance. Revenue reached $25.4 billion, up 5.9%, while adjusted EPS of $2.59 fell 7.5%, a decline the company attributed mostly to acquisitions. Innovative medicine sales rose 7.7% to $16.8 billion, led by Darzalex and Tremfya, but medtech revenue of $8.6 billion, up 2.5%, fell short of expectations and drove the post-earnings dip, with the cardiovascular unit hurt by safety and efficacy concerns about the Impella heart pumps. The article points to new drugs such as ICOTYDE and Imaavy as medium-term growth drivers and says the Ottava robotic surgery device could help medtech recover. The author argues investors should hold the stock for the long term, citing JNJ's 64 consecutive years of dividend increases.
- Johnson & Johnson Just Raised Its Sales Outlook Again. Here's Why the Dividend King Is Still a Buy.
Johnson & Johnson's third-quarter revenue rose 6% to $25.9 billion and adjusted EPS of $2.59 fell 7.5% year over year, both topping most analyst estimates, and the company raised its full-year 2026 operational sales growth guidance to 6.4% to 6.8%. However, MedTech revenue rose only 2.5% to $8.6 billion, short of the consensus of just over $8.7 billion, and the stock fell nearly 6% after the release; CFO Joe Wolk called the division's results 'disappointing,' and the company floated a spinoff of its DePuy Synthes orthopedics business sometime in 2027. The article notes MedTech accounts for about one-third of sales and under 20% of adjusted net income, while oncology grew more than 16% to $7.6 billion in the quarter, with J&J targeting at least $50 billion in oncology sales by 2030. It also highlights a forward dividend yield of about 2% backed by a 64-year dividend growth streak as a reason the stock may be easier to hold through volatility.
- Forget Casgevy: CRISPR Therapeutics' Heart-Disease Data Could Matter More
CRISPR Therapeutics developed Casgevy, the first approved therapy using the CRISPR gene-editing technique in 2023, and shares its rights with Vertex Pharmaceuticals (VRTX). The article argues that the investigational CTX310, which targets high LDL cholesterol and triglycerides, could matter more to the company's future as a possible one-time option, since more than 40 million U.S. patients have high LDL or TG levels versus about 60,000 addressable patients for Casgevy. In a Phase 1a trial reported in August, the highest dose cut mean TG by 48% and mean LDL by 53% in patients with certain genetic conditions, and Phase 1b data are due in early November. Risks include clinical and regulatory setbacks, high prices and difficult administration. The author views the company as fairly attractive, but only for investors comfortable with significant risk and volatility.
- Why Is CVS Health (CVS) Hiring A Top AI Leader For Pharmacy?
CVS Health has appointed Jack Hanlon as senior vice president of AI and Analytics for its retail and pharmacy operations, after he held senior data and analytics roles at Meta and Reddit. The role focuses on applying advanced AI and analytics across CVS pharmacy, front-store activity and customer programs. The article says the hire reinforces the company's focus on technology and AI-driven cost savings, tied to a decade-long plan to spend more than US$20b on technology and more than US$1b in operating expense savings already linked to AI and automation in claims, prior authorization and pharmacy operations. It adds that the move will matter more if upcoming quarterly results and 2027 guidance show concrete operating metrics linked to AI, rather than only more talk about tools and platforms.
- Biotech stocks are surging. How investors can play the new drug innovation boom
Biotech stocks are rallying: the iShares Biotechnology ETF (IBB) is up 24% through October 23, after a 28% gain in 2025, with two dozen of its 233 holdings more than doubling year-to-date. Moderna leads with a 587% surge, though its stock fell 18% after a leak of positive cancer-vaccine trial data. Analysts attribute the rally to clinical trial results, M&A, and technologies such as mRNA, genomics and AI, with about a dozen novel biologics approved by the FDA in 2025 out of 46 approvals and roughly 66 novel drugs in the pipeline. The Moderna–Merck melanoma drug showed a 42% reduction in recurrence or death when combined with Keytruda in Phase 3 and is targeted for FDA submission and launch in 2027. Gene-sequencing firm Illumina more than doubled this year, and 10x Genomics rose more than 300%.
- Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer
A late-stage trial found that adding Amgen's Imdelltra to AstraZeneca's Imfinzi cut the risk of death by 58% in patients with extensive-stage small cell lung cancer. Median overall survival rose to 21.1 months, compared with 12.7 months for Imfinzi alone, in patients whose cancer had not progressed after initial Imfinzi and chemotherapy. Nearly 80% of patients on the combination were alive at one year, versus 53% on Imfinzi alone. Imdelltra posted $288 million in second-quarter sales, up 115% year over year, after $627 million in global sales in 2025. Amgen said the results suggest earlier use of the drug could meaningfully alter the course of the disease, though the trial did not compare the combination with other first-line treatments.
Related markets
Latest news
- Should You Ignore the SpaceX Hype and Buy Rocket Lab Instead?
Space stocks surged after SpaceX's June IPO, but since then SpaceX shares have swung between $105 and $225 and Rocket Lab has fallen 65% from its June peak near $150. SpaceX's launch services revenue reached $1.8 billion, up 6%, while Starlink grew 69% to $5.2 billion with 13.6 million consumer broadband subscribers, and its AI segment, now called Super Intelligence, reached $7.6 billion, helped by an $84.5 billion compute leasing deal with Anthropic. Rocket Lab focuses purely on the space economy, relying on its Electron rocket, which can carry up to 660 pounds to low Earth orbit, and holds a backlog of nearly $2.4 billion, but its Neutron rocket has been delayed to 2027. SpaceX's $2.2 trillion market cap compares with $30 billion for Rocket Lab, and the two trade at about 70 and 40 times trailing sales. The author says SpaceX suits investors seeking broad exposure to AI and communications, while Rocket Lab is the purer aerospace option, though further Neutron delays could weigh on its shares in the near term.
- Gulf Nation Sends Good News to the World
Aramco is looking to raise the Petroline pipeline's capacity from about 7 million to 10 million barrels per day to reduce reliance on the Strait of Hormuz, which has been nearly blocked since the conflict began, and Saudi Energy Minister Prince Abdulaziz bin Salman said the expansion would take two to three years. Before the war, the route carried about 2 million barrels per day, and Aramco's first-quarter profit rose 25% after the pipeline reached its maximum of 7 million barrels per day. The pipeline has been hit by drones several times, and Houthi forces control the Bab al-Mandab area, keeping risks high. Professor Gilbert Metcalf of MIT Sloan said that reaching 10 million barrels per day would add about 2% to global supply, so the effect on prices may be limited. Kpler data show Hormuz exports in September averaged just under 9 million barrels per day, about 44% of February levels, although US Energy Secretary Chris Wright said Gulf oil flows had recovered 80-90%.
- Gold bar and gold ring prices on 25/10 at SJC, DOJI, PNJ, Bảo Tín Minh Châu and Phú Quý
On the morning of 25/10, SJC gold bars were quoted at 138.7–141.7 million VND per lượng (buy–sell), unchanged from 24/10. DOJI quoted 139–142 million VND per lượng, 300,000 VND higher than SJC on both sides. Domestic gold fell about 2 million VND per lượng over the past week. Globally, gold slid sharply as higher oil prices, inflation worries and expectations of tighter Fed policy outweighed safe-haven demand, touching 3,975.10 USD/ounce, its lowest since early June, before trading near 4,000 USD. In a Kitco survey, 7 of 17 analysts (41%) expected prices to keep falling, while 42% of 161 individual investors expected a rise.
- Flying Cars, Smart Homes, and Cracks in the AI Boom
This Motley Fool podcast, recorded Oct. 16, 2026, debates smart homes, flying cars, AI wearables and the recent sell-off in AI infrastructure stocks. The hosts view Apple's HomeView as a refined, incremental product that reinforces existing advantages rather than redefining the category, and note Apple is entering a home-device market already crowded with players like ADT and SimpliSafe. They compare Block's new restaurant device with Toast's established share and question whether Siri can justify a possible $19-a-month charge. The discussion also touches on a flying Tesla Roadster referenced for 2028.
- UPS Stock Is Down 57% From Its Record. Is It a Buy Before Its Oct. 27 Report?
UPS shares trade near $100, about 57% below their all-time closing high of $232.11, pushing the dividend yield to roughly 6.5% on a $1.64 quarterly payout. Management expects 2026 adjusted EPS of about $7.22, down about 44% from $12.94 in 2022, after the Amazon volume cut finished in June. In the second quarter, U.S. domestic revenue rose 6% and the segment's adjusted operating margin widened to 8%, helped by cost programs expected to deliver about $3 billion in 2026. Free cash flow is projected at about $5.5 billion against roughly $5.4 billion in dividends, and the stock trades near 13 times expected 2027 earnings versus about 19 times for the S&P 500. The author sees value for income investors willing to wait for the turnaround, though the Oct. 27 report and thin dividend coverage remain risks.
- Here where credit limits decreased the most in the US ( and why that bad )
WalletHub reports that average credit limits fell in 36 of 50 states year over year, with the largest decrease nearing 13%. Causes cited include rising credit card debt, delinquency, or declines in credit score or income; inflation also pushes people to charge more, raising credit utilization and delinquency risk. A sharp rise in utilization can lower a credit score, and late payments are reported to credit bureaus. Utah topped the list for the largest dollar decrease in credit limits despite a smaller percentage drop, since its residents had among the highest limits. Minnesota ranked second, with average limits down 8% from June 2025 to June 2026; in Montana the figure was 13%.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.